16 Hrs
Source:
المشهد
Heart Disease Drugs Fail to Help
Two trials of drugs from Novartis and Novo Nordisk failed to reduce major cardiovascular events, despite affecting their targeted factors. Pelacarsen lowered levels of lipoprotein(a) by 78%, but a trial involving more than 8,300 patients and lasting nearly five years did not show that it reduced deaths, heart attacks or strokes. Novo Nordisk’s drug reduced cardiac inflammation, but did not meet its goal of preventing major cardiovascular disease. The findings are particularly significant given the genetic link between lipoprotein(a) and risk factors in around 20% of the world’s population.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)